“After a series of strict reviews, verification, test and data analysis in accordance with the law and procedures, it is concluded that the known and potential benefits of Sinopharm’s new inactivated coronavirus vaccine are bigger than the known and potential risks, and it fully meets the pre-set requirements of conditional marketing standards,” he said.
Click Here to Visit Orignal Source of Article https://www.bbc.co.uk/news/world-asia-china-55498197
